- 18,420 followers
- 500+ connections
About
Due to the number of inquiries, I am not able to take intro calls regarding board roles. If you are interested in pitching board/advisor opportunities to me, please send details of the company or venture firm.
Vendors/CROs etc, please contact info@seaporttx.com to get connected to the right leaders within Seaport.
For jobs, please contact careers@seaporttx.com
Featured
- The initiation of BUOY-1 marks a significant milestone for Seaport’s pipeline, bringing us closer to a potential new treatment for major depression, which impacts around 280 million people globally – nearly 60 percent of whom also experience anxious distress. This is an important step on our journey to deliver new treatments for patients living with depression, anxiety, and other neuropsychiatric conditions.
Congratulations to the Seaport team on this progress!
- Our Seaport team kicked off the year with a special gathering to celebrate the holidays and reflect on our progress this past year. It was a great opportunity to connect as a team while enjoying making pizza, pasta, and desserts! We’re excited to carry this energy through 2026 as we continue our mission to serve those impacted by hashtagneuropsychiatric conditions, including hashtagdepression and hashtaganxiety. Here’s to another great year!
- Yesterday, our Co-founder and Chief Executive Officer, Daphne Zohar, presented at the J.P. Morgan Healthcare Conference, sharing the recent progress Seaport has made and our path forward as we tackle some of the biggest medical problems our population is facing today. With our clinically validated Glyph™ platform that has yielded a robust pipeline, we’re pleased with the key development milestones, including across our two clinical-stage programs: GlyphAllo™ (Glyph Allopregnanolone), which we’re advancing in a Phase 2b trial for the treatment of major depressive disorder, and GlyphAgo™ (Glyph Agomelatine), which we’re advancing in a Phase 1 proof-of-concept trial for the treatment of generalized anxiety disorder. We have a seasoned leadership team that has a proven track record of bringing new medicines to patients, and we look forward to continued progress toward developing potentially first-in-class and best-in-class drug candidates for hashtagdepression, hashtaganxiety, and other hashtagneuropsychiatric disorders with significant unmet need.
Daphne was also joined on stage by Steven Paul, M.D., Co-founder and Chair, and Michael C. Chen, Ph.D., Co-founder and Chief Scientific Officer for the Q&A portion of the presentation, and other members of our Seaport team at the conference. hashtagJPM26 hashtagJPMHC26
- Today we’re pleased to announce our $225 million oversubscribed Series B financing round. The syndicate was led by General Atlantic, with participation from funds and accounts advised by T. Rowe Price Associates, Inc., Foresite Capital, Invus, Goldman Sachs Alternatives, CPP Investments, and other new investors. Founding investors ARCH Venture Partners, Third Rock Ventures, and co-founder PureTech Health also participated.
We’re proud to partner with this group of new and existing investors who share our commitment of delivering better medicines for those suffering from hashtagdepression, hashtaganxiety and other hashtagneuropsychiatric disorders. The proceeds will be used to advance our clinical-stage pipeline of first and best-in-class medicines through important clinical milestones as well as further advance the capabilities of our Glyph™ technology platform. https://bwnews.pr/4eQ6FHm
Activity
18,420 followers
Loaded 9 Posts posts
- Daphne Zohar reposted this
- Daphne Zohar reposted this
hashtagMatias hashtagPediatricCancer hashtagChildhoodCancer hashtagPediatricOncology hashtagNeuroOncology hashtagCancerResearch hashtagPrecisionMedicine hashtagPrecisionOncology hashtagTranslationalResearch hashtagGenomics hashtagFunctionalGenomics hashtagRNAseq hashtagWGS hashtagMolecularTumorBoard hashtagLiquidBiopsy hashtagTargetedTherapy hashtagDrugResistance hashtagCompassionateUse hashtagExpandedAccess hashtagClinicalTrials hashtagBiotech hashtagPharma hashtagOncology hashtagEGFR hashtagHELP hashtagResearchers
Update on Matias (post-op, 15 January): new imaging shows the tumor is progressing more aggressively than before. It is now compressing nerves affecting his right leg, and Matias has lost the ability to walk.
A second surgical intervention is being considered.
We urgently need input from:
• Pediatric oncology specialists
• Translational / precision oncology researchers
• Biotech / pharma teams with experience in aggressive pediatric tumors, resistance mechanisms, and alternative targeted combinations (incl. EGFR pathways).
We are actively exploring (globally):
• Transfer to another country for care
• Advanced molecular re-analysis
• DNA+RNA profiling (RNA-seq / WGS / comprehensive panels)
• Novel drug combinations / rational targeted + adjunct approaches
• Compassionate use / expanded access programs
• Experimental therapeutic options / clinical trials
If you are a clinician, researcher, or can connect us to someone in pediatric precision oncology, please message me or comment with a contact.
Every connection matters. Every share increases the chance of finding the right path.
To support Matias (GoFundMe):
https://lnkd.in/dMzath8G
Experience
-
-
-
We are charting a proven path in neuropsychiatry www.SeaportTX.com
-
-
-
-
-
Founder, CEO & Board Member at PureTech Health, Boston, MA · http://www.puretechhealth.com
-
-
Skills
Recommendations
Nothing to see for now
-
-
-
Mark was a key investor in my former company and is thoughtful, experienced and pragmatic. Was a pleasure to work with him!
-
-
Tune in at 12pm ET: https://lnkd.in/eB8a45n2